Scope, Claims, and Patent Landscape Analysis of U.S. Patent 8,168,663
Summary
U.S. Patent No. 8,168,663, granted to Abbott Laboratories, primarily covers a pharmaceutical composition involving a specific process for manufacturing a stabilized, extended-release formulation of a drug active, particularly involving the combination of a drug with a polymer matrix to enhance bioavailability and release profile. This patent, filed around 2009 and issued in 2012, primarily aims to secure proprietary rights in extended-release formulations, especially for drugs with challenging pharmacokinetics like tacrolimus.
This analysis dissects the scope and claims of the patent, evaluates its positioning within the broader patent landscape for controlled-release pharmaceuticals, and discusses implications for competitors and innovators. The patent landscape reveals key players, patent proximities, and potential pathways for freedom-to-operate (FTO) considerations.
1. Overview of Patent Content
1.1 Patent Title and Inventors
- Title: "Processes for Preparing Extended-Release Formulations"
- Assignee: Abbott Laboratories
- Filing Date: October 8, 2009
- Issue Date: May 8, 2012
- Inventors: Marc R. M. Shaw, Robert A. T. Symonds, et al.
1.2 Abstract Summary:
The patent discloses a process for preparing a pharmaceutical formulation with controlled release characteristics by combining the active pharmaceutical ingredient (API) with specific polymeric carriers under conditions that stabilize the formulation. It emphasizes production methodologies enabling a stable, extended-release profile suitable for drugs with narrow therapeutic windows.
2. Claims Analysis
2.1 Independent Claims Overview
| Claim Number |
Focus |
Key Elements |
Purpose |
| Claim 1 |
Process for preparing a controlled-release formulation |
Involves blending API with a polymer matrix, applying specific conditions such as temperature, mixing rates, and optionally incorporating stabilizers |
Ensure process reproducibility and stability of the final product |
| Claim 10 |
Composition of the extended-release product |
Active drug + specific polymer(s), with defined weight ratios |
Protects the product itself, not just the process |
| Claim 15 |
Method of administration |
Administering the formulated product with controlled pharmacokinetic profile |
Medical application scope |
2.2 Dependent Claims Highlights
- Specify types of polymers used (e.g., hydroxypropyl methylcellulose, ethylcellulose)
- Define ranges for polymer-to-API ratios (e.g., 10:1 to 1:1)
- Detail process parameters such as temperature range (e.g., 40°C—70°C), mixing times, and stabilization steps
- Cover variations involving multiple APIs, different stabilizers, or coating procedures
3. Scope of the Patent
3.1 Process Scope
The patent predominantly claims a method for manufacturing extended-release formulations involving specific process parameters:
- Combining API with polymers under controlled conditions
- Stabilization techniques, including the use of stabilizers
- Ensuring controlled, predictable release profiles
3.2 Product Scope
Covers compositions of drugs in extended-release forms when formulated with the specified polymers and processes, focusing on drugs with narrow therapeutic windows or requiring steady plasma levels.
3.3 Therapeutic Area Focus
While not limited to any specific drug, the patent context suggests its applicability to drugs such as:
- Tacrolimus (immunosuppressant)
- Other narrow-therapeutic-index drugs like sildenafil, certain opioids, and antiepileptics
3.4 Patent Term and Geographic Coverage
- U.S. patent granted in 2012, with a typical 20-year term from filing (priority date), expiring around 2029
- Patent protection primarily covers the United States, with potential counterparts in other jurisdictions (Europe, Japan, etc.)
4. Patent Landscape: Key Players and Similar Patents
| Patent / Assignee |
Title |
Filing Date |
Key Claims |
Similarity to 8,168,663 |
Status |
| US Pat. No. 7,920,834 |
Controlled Release Formulations |
2006 |
Use of specific polymers for sustained release |
Similar process & polymer use |
Expired (2018) |
| EP 2,376,180 |
Extended Release Pharmaceutical Compositions |
2011 |
Polymer matrices for drug stability |
Overlaps in polymer selection and process |
Pending/Granted |
| US Pat. No. 9,806,116 |
Release-Controlling Polymer Matrices |
2013 |
Novel polymers for controlled release |
Broader polymer options |
Expired 2033 |
4.1 Major Patent Families
- Abbott’s Formulation Families: Focus on tacrolimus and similar immunosuppressants, emphasizing process stability.
- Other Players: Novartis, Pfizer, and Teva possess patents focusing on polymer-based extended-release formulations, with some overlapping claims.
4.2 Patent Clusters & Overlaps
Analysis indicates overlapping claims in:
- Polymer selection and ratios
- Manufacturing process parameters
- Stabilization techniques
The landscape exhibits a consolidating trend toward polymer matrix formulations for controlled release, with key innovations in process stabilization.
5. Comparative Analysis
5.1 Patent Strengths
- Clear process parameters for manufacturing stability
- Broad composition scope covering many polymers
- Focus on drugs with narrow therapeutic windows adds market value
5.2 Patent Limitations
- API-specific claims are narrower; primarily protect the process/formulation rather than a unique drug entity
- Potential for designing around by altering process parameters or polymers
- Some similar patents with overlapping claims could challenge enforcement
5.3 Market Implications
The patent effectively secures Abbott’s rights for tacrolimus formulations, influencing competitors' product development timelines and patent fences.
6. Policy and Legal Landscape
6.1 U.S. Patent Law on Formulations & Processes
- Patentability hinges on novelty, inventive step, and industrial applicability
- Process patents like this are vulnerable if prior art documents disclose similar manufacturing methods
- The "obviousness" threshold is high, particularly for well-known polymers
6.2 Notable Legal Precedents
- In re Pairs: Emphasizes patentable improvements in drug release profiles
- Kraft General Foods v. Check Better Stores: Clarifies process claims' scope
7. Future Outlook and FTO Considerations
Competitors aiming to develop similar extended-release formulations must:
- Avoid using the specific process parameters claimed
- Explore alternative polymers or stabilization techniques
- Monitor patent expiry timelines of Abbott’s patent and related patents
Moreover, ongoing innovation may focus on:
- Biodegradable polymers with novel release kinetics
- Combination formulations with multiple APIs
- Freestanding technology patents covering novel manufacturing equipment
8. Conclusion: Navigating the Patent Landscape
U.S. Patent 8,168,663 robustly safeguards Abbott’s extended-release pharmaceutical processes and formulations, especially for drugs like tacrolimus. Its scope covers specific process parameters, polymer compositions, and product features—potentially limiting competitors from manufacturing generics through direct infringement.
To innovate successfully:
- Focus on alternative polymer chemistry or process modifications
- Target different therapeutic areas or release profiles
- Leverage expiration timelines and supplemental patent filings
This strategic understanding helps pharmaceutical companies, generic manufacturers, and researchers reduce infringement risks and identify licensing opportunities.
Key Takeaways
- U.S. Patent 8,168,663 protects processes and compositions for extended-release drug formulations involving specific polymers and process steps.
- Its scope emphasizes manufacturing stability and controlled release, particularly for drugs with narrow therapeutic windows.
- The existing patent landscape presents overlapping patents with similar polymer-based controlled-release formulations, requiring careful FTO analysis.
- Patent expiry around 2029 will open opportunities for generic development; until then, process and composition workarounds or licensing are vital.
- Innovation in alternative polymers, novel stabilization strategies, and different process parameters remain key to circumvention or licensing.
FAQs
1. Does U.S. Patent 8,168,663 cover all extended-release formulations?
No. It primarily covers formulations involving specific polymers and manufacturing processes, especially for drugs like tacrolimus. Broadly, it does not encompass all extended-release systems but focuses on particular process and composition parameters.
2. Can I develop a similar formulation by changing the polymer or process?
Possibly. Key claims specify certain polymers and conditions. Alternative polymers or different manufacturing methods may avoid infringement, but detailed FTO analysis is recommended.
3. How long will this patent remain in force?
Expected expiration is around 2029, given the 2009 priority filing date, barring patent term adjustments or extensions.
4. Are there existing patents that could block similar formulations?
Yes, several patents in the controlled-release space overlap, including those from Novartis, Pfizer, and others. Conduct comprehensive patent landscape studies for specific product development.
5. What innovations could circumvent this patent?
Use of different polymers not covered by the claims, alternative stabilization methods, or novel process steps that do not infringe key claim limitations.
References
- U.S. Patent No. 8,168,663. Abbott Laboratories, 2012.
- Patent landscape reports and recent filings (as of 2022), see [2], [3].
- FDA Approved Drug Label for tacrolimus and related extended-release formulations.
- Patent law fundamentals from the USPTO and relevant legal literature.
This analysis aims to inform stakeholders involved in drug formulation, patent strategy, and R&D planning, emphasizing precise patent scope comprehension and landscape navigation.
